Citadel Advisors’s Eton Pharmaceutcials ETON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$740K Buy
+30,000
New +$525K ﹤0.01% 8388
2025
Q2
Sell
-13,400
Closed -$174K 13218
2025
Q1
$174K Buy
13,400
+9,200
+219% +$139K ﹤0.01% 10647
2024
Q4
$55.9K Buy
4,200
+3,700
+740% +$37.5K ﹤0.01% 12270
2024
Q3
$3K Sell
500
-500
-50% -$2.11K ﹤0.01% 13700
2024
Q2
$3.29K Buy
+1,000
New +$3.5K ﹤0.01% 13609
2024
Q1
Sell
-3,100
Closed -$13.6K 14770
2023
Q4
$13.6K Buy
3,100
+1,100
+55% +$4.41K ﹤0.01% 12923
2023
Q3
$8.34K Buy
2,000
+900
+82% +$3.47K ﹤0.01% 13196
2023
Q2
$3.84K Buy
1,100
+1,000
+1,000% +$3.68K ﹤0.01% 13654
2023
Q1
$385 Buy
+100
New +$365 ﹤0.01% 14506
2022
Q1
Sell
-15,600
Closed -$67K 13844
2021
Q4
$67K Sell
15,600
-6,000
-28% -$28.7K ﹤0.01% 13065
2021
Q3
$109K Sell
21,600
-7,100
-25% -$36.9K ﹤0.01% 12768
2021
Q2
$177K Buy
+28,700
New +$213K ﹤0.01% 12306

Other funds holding ETON

Citadel Advisors's ETON Position: Q1 2026 in Review

Citadel Advisors increased its Eton Pharmaceutcials (ETON) stake by 45% in Q1 2026, buying an estimated $589K and bringing the position to 107,815 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #5499.

Citadel Advisors first reported a position in ETON in Q3 2020 and has held it in 14 quarters since. 116 funds tracked by Wall St. Rank hold ETON as of Q1 2026.

  • Citadel Advisors held 107,815 shares of Eton Pharmaceutcials worth $2.66M as of Q1 2026.
  • Citadel Advisors bought 33,671 Eton Pharmaceutcials shares in Q1 2026, an estimated $589K.
  • Eton Pharmaceutcials made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5499 holding.
  • Citadel Advisors first reported a position in Eton Pharmaceutcials in Q3 2020 and has held it in 14 quarters since.
  • 116 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.